Polaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug

MT Newswires Live

2025/04/15

Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.

The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.

Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527451153"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527451153\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527451153?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-15 15:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527451153","market":"us","top_or_hot":-1,"title":"Polaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug","media":"MT Newswires Live","content":"<html><body><p> Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.</p><p>The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.</p><p>Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolaris Unit Signs Two Sales Deals for Malignant Pleural Mesothelioma Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-15 15:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.</p><p>The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.</p><p>Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PII","symbol_name":"北極星","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527451153","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527451153","pubTimestamp":1744703725,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Polaris Group's  unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PII":"北极星","5BI.SI":"POLARIS公司"},"translate_title":"北极星子公司签署两项恶性胸膜间皮瘤药物销售协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"5BI.SI":1,"PII":1},"content_text":"Polaris Group's (TPE:6550) unit Polaris Pharmaceuticals signed two exclusive regional agreements to commercialize its drug for treating malignant pleural mesothelioma, according to two separate Monday Taiwan Exchange filings.The first commercialization and channel sales collaboration deal for the drug, dubbed ADI-PEG 20, was signed with Er-Kim Pharmaceuticals. The contract has a term of eight years and covers the EMEA region.Meanwhile, another commercialization and sales deal was inked with Tabuk Pharmaceutical Manufacturing for the Gulf Cooperation Council market, valid for six years.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}